Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Epoprostenol
Drug ID BADD_D00788
Description A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Indications and Usage For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Marketing Status approved
ATC Code B01AC09
DrugBank ID DB01240
KEGG ID D00106
MeSH ID D011464
PubChem ID 5282411
TTD Drug ID D0V0IX
NDC Product Code 66215-402; 62756-060; 66215-403; 62287-123; 62756-059
UNII DCR9Z582X0
Synonyms Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 35121-78-9
SMILES CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinorrhoea22.12.03.0210.000584%
Right ventricular failure02.05.03.0020.002015%Not Available
Salivary gland enlargement07.06.03.0020.000082%Not Available
Scleroderma15.06.01.002; 10.04.07.001; 23.03.02.0050.000247%Not Available
Seizure17.12.03.0010.000864%
Sensory loss17.02.07.0070.000123%Not Available
Sepsis11.01.11.003--
Shock24.06.02.0020.000123%Not Available
Sickle cell anaemia with crisis01.04.02.0010.000123%Not Available
Sinus congestion22.04.06.0010.000181%Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.0050.000263%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000263%Not Available
Skin infection23.11.04.007; 11.01.12.003--
Skin irritation23.03.04.0090.000905%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000543%Not Available
Skin ulcer23.07.03.003; 24.04.03.0070.000164%
Sluggishness08.01.01.0040.000082%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Splenomegaly01.09.02.0010.000329%Not Available
Stress19.06.02.0040.000321%Not Available
Sudden death08.04.01.003; 02.03.04.0130.000206%
Supraventricular tachycardia02.03.03.0120.000164%
Swelling08.01.03.0150.001168%Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.0180.000609%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.001530%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000304%Not Available
Tachycardia02.03.02.0070.001127%Not Available
Tension19.06.02.005--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages